HROW:NASDAQ
Harrow Inc
၂၉.၄၂ US$
arrow_upward
+၀.၁၉%(+၀.၀၅၅) 1D
အောက် ၁၂, GMT-၄ ၁၅:၀၀:၅၁ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HROW...
Open
၂၉.၃၈ US$
High
၂၉.၇၃ US$
Low
၂၈.၈၆ US$
Mkt. cap
၁၁၀.၂၇ ဋေ
Avg. vol.
၅.၈၀ သိန်း
Volume
၃.၄၂ သိန်း
52-wk high
၅၄.၈၅ US$
52-wk low
၂၇.၀၀ US$
EPS
-၁.၀၀ US$
Beta
၀.၁၉
Shares outstanding
၃.၇၅ ကုဋေ
No. of employees
၃၇၃
Open
၂၉.၃၈ US$
High
၂၉.၇၃ US$
Low
၂၈.၈၆ US$
Mkt. cap
၁၁၀.၂၇ ဋေ
Avg. vol.
၅.၈၀ သိန်း
Volume
၃.၄၂ သိန်း
52-wk high
၅၄.၈၅ US$
52-wk low
၂၇.၀၀ US$
EPS
-၁.၀၀ US$
Beta
၀.၁၉
Shares outstanding
၃.၇၅ ကုဋေ
No. of employees
၃၇၃
News stories
From web sources and news partners
Nashville Post
·
ပြီးခဲ့သည့် ၆ နာရီ
Harrow stock seeks rebound
Stock Traders Daily
·
ပြီးခဲ့သည့် ၉ နာရီ
(HROW) and the Role of Price-Sensitive Allocations
Simply Wall Street
·
ပြီးခဲ့သည့် ၃ ရက်
Clinical Data Showcase Could Be A Game Changer For Harrow (HROW)
Profile
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
About Harrow Inc
CEOMark L. Baum Esq.
Employees၃၇၃
Founded၂၀၁၂
Headquartersနက်ရှ်ဗီးလ်, တင်နက်ဆီပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websiteharrow.com